NFKB1 and metabolic dysfunction-associated steatotic liver disease: In NAFLD, it functions oppositely in hepatocytes and macrophages, exacerbating hepatic steatosis through the GH signaling pathway in hepatocytes, while inhibiting inflammation in macrophages by limiting the NF-κB signaling and inflammasome pathways [29,30].